title: Rituximab in critically ill patients.
abstract: Rituximab is a monoclonal chimeric antibody used in the treatment of CD20-positive B-cell malignancies and rheumatoid arthritis. However, it is used in several other off-label indications including acute graft-versus-host disease. We sought to critically examine the role of rituximab in the treatment of acute graft versus host disease (aGVHD) in critically ill patients and the potential associations with infectious complications in transplant recipients.
authors.affiliation: Department of Critical Care, Medical School, University of Athens, Attikon University Hospital, Athens, Greece. gdimop@med.uoa.gr
authors.forename: G
authors.initials: G
authors.lastname: Dimopoulos
authors.forename: A
authors.initials: A
authors.lastname: Armaganidis
authors.forename: G
authors.initials: G
authors.lastname: Poulakou
authors.forename: D K
authors.initials: DK
authors.lastname: Matthaiou
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D003422:Critical Care; D016638:Critical Illness / Q000401:mortality; D006086:Graft vs Host Disease / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007239:Infections / Q000150:complications; D056687:Off-Label Use; D016377:Organ Transplantation; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab